Cellosaurus logo
expasy logo

Cellosaurus HCC2998 (CVCL_1266)

[Text version]
Cell line name HCC2998
Synonyms HCC-2998; HCC.2998; HCC 2998; Hamon Cancer Center 2998
Accession CVCL_1266
Resource Identification Initiative To cite this cell line use: HCC2998 (RRID:CVCL_1266)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Part of: JFCR39 cancer cell line panel.
Part of: MD Anderson Cell Lines Project.
Part of: NCI-60 cancer cell line panel.
Population: Caucasian.
Doubling time: 44.40 hours (PubMed=25944804); 31.5 hours (NCI-DTP=HCC-2998).
Microsatellite instability: Stable (MSS) (PubMed=24755471; PubMed=25926053; PubMed=28683746; Sanger).
Omics: Array-based CGH.
Omics: CNV analysis.
Omics: CRISPR phenotypic screen.
Omics: Deep exome analysis.
Omics: Deep proteome analysis.
Omics: Deep quantitative phosphoproteome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: Fluorescence phenotype profiling.
Omics: lncRNA expression profiling.
Omics: Metabolome analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Sequence variations
  • Mutation; HGNC; 583; APC; Simple; p.Arg168Ile (c.503G>T); Zygosity=Heterozygous (PubMed=17088437; PubMed=24755471; PubMed=28179481; Cosmic-CLP=905971; DepMap=ACH-001081).
  • Mutation; HGNC; 583; APC; Simple; p.Leu665Ter (c.1994T>A); Zygosity=Heterozygous (PubMed=17088437; PubMed=24755471; PubMed=28179481; Cosmic-CLP=905971; DepMap=ACH-001081).
  • Mutation; HGNC; 583; APC; Simple; p.Arg1450Ter (c.4348C>T); ClinVar=VCV000194585; Zygosity=Heterozygous (PubMed=17088437; PubMed=24755471; PubMed=28179481; Cosmic-CLP=905971; DepMap=ACH-001081).
  • Mutation; HGNC; 583; APC; Simple; p.Ser1864Tyr (c.5591C>A); Zygosity=Heterozygous (PubMed=17088437; PubMed=24755471; PubMed=28179481; Cosmic-CLP=905971; DepMap=ACH-001081).
  • Mutation; HGNC; 583; APC; Simple; p.Ile2167Ser (c.6500T>G); Zygosity=Heterozygous (PubMed=17088437; PubMed=24755471; PubMed=28179481; Cosmic-CLP=905971; DepMap=ACH-001081).
  • Mutation; HGNC; 583; APC; Simple; p.Asn2720Lys (c.8160T>G); Zygosity=Heterozygous (PubMed=17088437; PubMed=24755471; PubMed=28179481; Cosmic-CLP=905971; DepMap=ACH-001081).
  • Mutation; HGNC; 11110; ARID1A; Simple; p.Arg1989Ter (c.5965C>T); ClinVar=VCV000225842; Zygosity=Heterozygous (Cosmic-CLP=905971; DepMap=ACH-001081).
  • Mutation; HGNC; 795; ATM; Simple; p.Glu277Ter (c.829G>T); ClinVar=VCV000234216; Zygosity=Heterozygous (Cosmic-CLP=905971; DepMap=ACH-001081).
  • Mutation; HGNC; 795; ATM; Simple; p.Arg337Cys (c.1009C>T); ClinVar=VCV000127327; Zygosity=Heterozygous (Cosmic-CLP=905971; DepMap=ACH-001081).
  • Mutation; HGNC; 6407; KRAS; Simple; p.Ala146Thr (c.436G>A); ClinVar=VCV000197243; Zygosity=Heterozygous (PubMed=16969076; PubMed=20570890; PubMed=28683746; Cosmic-CLP=905971; DepMap=ACH-001081).
  • Mutation; HGNC; 9588; PTEN; Simple; p.Arg130Gln (c.389G>A); ClinVar=VCV000007829; Zygosity=Heterozygous (PubMed=24755471; PubMed=28683746; Cosmic-CLP=905971; DepMap=ACH-001081).
  • Mutation; HGNC; 9588; PTEN; Simple; p.Phe341Val (c.1021T>G); ClinVar=VCV000495806; Zygosity=Heterozygous (PubMed=24755471; PubMed=28683746; Cosmic-CLP=905971; DepMap=ACH-001081).
  • Mutation; HGNC; 9829; RAF1; Simple; p.Ser257Leu (c.770C>T); ClinVar=VCV000013957; Zygosity=Heterozygous (Cosmic-CLP=905971; DepMap=ACH-001081).
  • Mutation; HGNC; 9884; RB1; Simple; p.Glu137Ter (c.409G>T); ClinVar=VCV000126810; Zygosity=Heterozygous (PubMed=17088437; Cosmic-CLP=905971; DepMap=ACH-001081).
  • Mutation; HGNC; 6768; SMAD2; Simple; p.Ser276Leu (c.827C>T); ClinVar=VCV002097524; Zygosity=Heterozygous (PubMed=24755471; Cosmic-CLP=905971; DepMap=ACH-001081).
  • Mutation; HGNC; 6768; SMAD2; Simple; p.Arg321Gln (c.962G>A); Zygosity=Heterozygous (PubMed=24755471; Cosmic-CLP=905971; DepMap=ACH-001081).
  • Mutation; HGNC; 6769; SMAD3; Simple; p.Ser266Leu (c.797C>T); ClinVar=VCV001417802; Zygosity=Heterozygous (PubMed=24755471; Cosmic-CLP=905971; DepMap=ACH-001081).
  • Mutation; HGNC; 11998; TP53; Simple; p.Arg213Ter (c.637C>T); ClinVar=VCV000043590; Zygosity=Heterozygous (PubMed=15900046; PubMed=17088437; PubMed=18277095; PubMed=24755471; PubMed=28683746; Cosmic-CLP=905971; DepMap=ACH-001081).
HLA typing Source: PubMed=15748285
Class I
HLA-AA*02,24
HLA-BB*37:01,40:06:01
HLA-CC*04,06:02
Class II
HLA-DPDPB1*04:01
HLA-DQDQB1*03:01:01,05:02:01
HLA-DRDRB1*11,16
Genome ancestry Source: PubMed=30894373

Origin% genome
African1.41
Native American0
East Asian, North0
East Asian, South1.46
South Asian8.24
European, North35.72
European, South53.15
Disease Colon adenocarcinoma (NCIt: C4349)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Sex unspecified
Age at sampling Age unspecified
Category Cancer cell line
STR profile Source(s): Cosmic-CLP=905971; PubMed=19372543; PubMed=25926053

Markers:
AmelogeninX
CSF1PO11,13
D2S133818,23
D3S135817,19
D5S81812
D7S82010,11
D8S117911,14
D13S31711,12
D16S5399,12
D18S5112,15
D19S43312,15
D21S1129,30
FGA25
TH017,9.3
TPOX8,11
vWA18,19

Run an STR similarity search on this cell line
Web pages https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm
https://strap.nci.nih.gov/celline_detail.php?sample_id=16
https://tcpaportal.org/mclp/
Publications

PubMed=3335022
Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.
Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.
Cancer Res. 48:589-601(1988)

PubMed=2041050; DOI=10.1093/jnci/83.11.757
Monks A., Scudiero D.A., Skehan P., Shoemaker R.H., Paull K.D., Vistica D.T., Hose C.D., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M., Campbell H., Mayo J.G., Boyd M.R.
Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.
J. Natl. Cancer Inst. 83:757-766(1991)

PubMed=10700174; DOI=10.1038/73432
Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T., Iyer V.R., Jeffrey S.S., van de Rijn M., Waltham M.C., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O.
Systematic variation in gene expression patterns in human cancer cell lines.
Nat. Genet. 24:227-235(2000)

PubMed=15748285; DOI=10.1186/1479-5876-3-11; PMCID=PMC555742
Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L., Morse H.C. 3rd, Stroncek D., Marincola F.M.
HLA class I and II genotype of the NCI-60 cell lines.
J. Transl. Med. 3:11.1-11.8(2005)

PubMed=15900046; DOI=10.1093/jnci/dji133
Mashima T., Oh-hara T., Sato S., Mochizuki M., Sugimoto Y., Yamazaki K., Hamada J.-i., Tada M., Moriuchi T., Ishikawa Y., Kato Y., Tomoda H., Yamori T., Tsuruo T.
p53-defective tumors with a functional apoptosome-mediated pathway: a new therapeutic target.
J. Natl. Cancer Inst. 97:765-777(2005)

PubMed=16969076; DOI=10.4161/cbt.5.8.3251; PMCID=PMC2714972
Edkins S., O'Meara S., Parker A., Stevens C., Reis M., Jones S., Greenman C.D., Davies H.R., Dalgliesh G.L., Forbes S., Hunter C., Smith R., Stephens P.J., Goldstraw P., Nicholson A., Chan T.-L., Velculescu V.E., Yuen S.T., Leung S.Y., Stratton M.R., Futreal P.A.
Recurrent KRAS codon 146 mutations in human colorectal cancer.
Cancer Biol. Ther. 5:928-932(2006)

PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433; PMCID=PMC2705832
Ikediobi O.N., Davies H.R., Bignell G.R., Edkins S., Stevens C., O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L., Buck G., Butler A.P., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C., Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A., Mironenko T., Parker A., Perry J., Raine K.M., Richardson D., Shepherd R., Small A., Smith R., Solomon H., Stephens P.J., Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.
Mol. Cancer Ther. 5:2606-2612(2006)

PubMed=18277095; DOI=10.4161/cbt.7.5.5712
Berglind H., Pawitan Y., Kato S., Ishioka C., Soussi T.
Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination.
Cancer Biol. Ther. 7:699-708(2008)

PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921; PMCID=PMC4020356
Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y., Chanock S.J., Weinstein J.N.
DNA fingerprinting of the NCI-60 cell line panel.
Mol. Cancer Ther. 8:713-724(2009)

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113
Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20570890; DOI=10.1158/0008-5472.CAN-10-0192; PMCID=PMC2943514
Janakiraman M., Vakiani E., Zeng Z.-S., Pratilas C.A., Taylor B.S., Chitale D., Halilovic E., Wilson M., Huberman K., Ricarte Filho J.C.M., Persaud Y., Levine D.A., Fagin J.A., Jhanwar S.C., Mariadason J.M., Lash A., Ladanyi M., Saltz L.B., Heguy A., Paty P.B., Solit D.B.
Genomic and biological characterization of exon 4 KRAS mutations in human cancer.
Cancer Res. 70:5901-5911(2010)

PubMed=20606684; DOI=10.1038/sj.bjc.6605780; PMCID=PMC2920028
Bracht K., Nicholls A.M., Liu Y., Bodmer W.F.
5-fluorouracil response in a large panel of colorectal cancer cell lines is associated with mismatch repair deficiency.
Br. J. Cancer 103:340-346(2010)

PubMed=22068913; DOI=10.1073/pnas.1111840108; PMCID=PMC3219108
Gillet J.-P., Calcagno A.M., Varma S., Marino M., Green L.J., Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V., Padmanabhan R., Davidson B., Ganapathi R., Sood A.K., Rueda B.R., Ambudkar S.V., Gottesman M.M.
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.
Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011)

PubMed=22336246; DOI=10.1016/j.bmc.2012.01.017
Kong D.-X., Yamori T.
JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
Bioorg. Med. Chem. 20:1947-1951(2012)

PubMed=22347499; DOI=10.1371/journal.pone.0031628; PMCID=PMC3276511
Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.
Mass homozygotes accumulation in the NCI-60 cancer cell lines as compared to HapMap trios, and relation to fragile site location.
PLoS ONE 7:E31628-E31628(2012)

PubMed=22384151; DOI=10.1371/journal.pone.0032096; PMCID=PMC3285665
Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H., Yoon C.N., Chang Y.-T.
Identification of cancer cell-line origins using fluorescence image-based phenomic screening.
PLoS ONE 7:E32096-E32096(2012)

PubMed=22628656; DOI=10.1126/science.1218595; PMCID=PMC3526189
Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L., Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.
Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.
Science 336:1040-1044(2012)

PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342; PMCID=PMC4893961
Abaan O.D., Polley E.C., Davis S.R., Zhu Y.-L.J., Bilke S., Walker R.L., Pineda M.A., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L., Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.
Cancer Res. 73:4372-4382(2013)

PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018
Moghaddas Gholami A., Hahne H., Wu Z.-X., Auer F.J., Meng C., Wilhelm M., Kuster B.
Global proteome analysis of the NCI-60 cell line panel.
Cell Rep. 4:609-620(2013)

PubMed=24279929; DOI=10.1186/2049-3002-1-20; PMCID=PMC4178206
Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R., Hirshfield K.M., Oltvai Z.N., Vazquez A.
The metabolic demands of cancer cells are coupled to their size and protein synthesis rates.
Cancer Metab. 1:20.1-20.13(2013)

PubMed=24670534; DOI=10.1371/journal.pone.0092047; PMCID=PMC3966786
Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.
High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.
PLoS ONE 9:E92047-E92047(2014)

PubMed=24755471; DOI=10.1158/0008-5472.CAN-14-0013
Mouradov D., Sloggett C., Jorissen R.N., Love C.G., Li S., Burgess A.W., Arango D., Strausberg R.L., Buchanan D., Wormald S., O'Connor L., Wilding J.L., Bicknell D.C., Tomlinson I.P.M., Bodmer W.F., Mariadason J.M., Sieber O.M.
Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.
Cancer Res. 74:3238-3247(2014)

PubMed=25926053; DOI=10.1038/ncomms8002
Medico E., Russo M., Picco G., Cancelliere C., Valtorta E., Corti G., Buscarino M., Isella C., Lamba S., Martinoglio B., Veronese S., Siena S., Sartore-Bianchi A., Beccuti M., Mottolese M., Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.
The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets.
Nat. Commun. 6:7002.1-7002.10(2015)

PubMed=25944804; DOI=10.1158/1078-0432.CCR-14-2457
Bazzocco S., Dopeso H., Carton-Garcia F., Macaya I., Andretta E., Chionh F., Rodrigues P., Garrido M., Alazzouzi H., Nieto R., Sanchez A., Schwartz S. Jr., Bilic J., Mariadason J.M., Arango D.
Highly expressed genes in rapidly proliferating tumor cells as new targets for colorectal cancer treatment.
Clin. Cancer Res. 21:3695-3704(2015)

PubMed=27377824; DOI=10.1038/sdata.2016.52; PMCID=PMC4932877
Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J., Vandesompele J.
Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR.
Sci. Data 3:160052-160052(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=27807467; DOI=10.1186/s13100-016-0078-4; PMCID=PMC5087121
Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J., Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.
A map of mobile DNA insertions in the NCI-60 human cancer cell panel.
Mob. DNA 7:20.1-20.11(2016)

PubMed=28179481; DOI=10.1158/1535-7163.MCT-16-0578
Tanaka N., Mashima T., Mizutani A., Sato A., Aoyama A., Gong B., Yoshida H., Muramatsu Y., Nakata K., Matsuura M., Katayama R., Nagayama S., Fujita N., Sugimoto Y., Seimiya H.
APC mutations as a potential biomarker for sensitivity to tankyrase inhibitors in colorectal cancer.
Mol. Cancer Ther. 16:752-762(2017)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=28683746; DOI=10.1186/s12943-017-0691-y; PMCID=PMC5498998
Berg K.C.G., Eide P.W., Eilertsen I.A., Johannessen B., Bruun J., Danielsen S.A., Bjornslett M., Meza-Zepeda L.A., Eknaes M., Lind G.E., Myklebost O., Skotheim R.I., Sveen A., Lothe R.A.
Multi-omics of 34 colorectal cancer cell lines -- a resource for biomedical studies.
Mol. Cancer 16:116.1-116.16(2017)

PubMed=28854368; DOI=10.1016/j.celrep.2017.08.010; PMCID=PMC5583477
Roumeliotis T.I., Williams S.P., Goncalves E., Alsinet C., Del Castillo Velasco-Herrera M., Aben N., Ghavidel F.Z., Michaut M., Schubert M., Price S., Wright J.C., Yu L., Yang M., Dienstmann R., Guinney J.H., Beltrao P., Brazma A., Pardo M., Stegle O., Adams D.J., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Choudhary J.S.
Genomic determinants of protein abundance variation in colorectal cancer cells.
Cell Rep. 20:2201-2214(2017)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=30971826; DOI=10.1038/s41586-019-1103-9
Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M., Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R., Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P., van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L., Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Nature 568:511-516(2019)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cross-references
Cell line collections (Providers) NCI-DTP; HCC-2998
Cell line databases/resources CLO; CLO_0009962
cancercelllines; CVCL_1266
Cell_Model_Passport; SIDM00118
ColonAtlas; HCC2998
Cosmic-CLP; 905971
DepMap; ACH-001081
LINCS_LDP; LCL-1191
SKY/M-FISH/CGH; 2794
Anatomy/cell type resources BTO; BTO:0003322
CRISP screens repositories BioGRID_ORCS_Cell_line; 872
Chemistry resources ChEMBL-Cells; CHEMBL3308074
ChEMBL-Targets; CHEMBL613855
GDSC; 905971
PharmacoDB; HCC2998_497_2019
PubChem_Cell_line; CVCL_1266
Encyclopedic resources Wikidata; Q54881683
Experimental variables resources EFO; EFO_0005370
Gene expression databases ArrayExpress; E-MTAB-783
ArrayExpress; E-MTAB-3610
GEO; GSM2146
GEO; GSM50187
GEO; GSM50251
GEO; GSM743442
GEO; GSM750796
GEO; GSM799330
GEO; GSM799393
GEO; GSM846354
GEO; GSM844550
GEO; GSM844551
GEO; GSM1153401
GEO; GSM1178115
GEO; GSM1178116
GEO; GSM1178117
GEO; GSM1181249
GEO; GSM1181265
GEO; GSM1346873
GEO; GSM1448169
GEO; GSM1669856
GEO; GSM2124654
GEO; GSM2550000
Polymorphism and mutation databases Cosmic; 875899
Cosmic; 905971
Cosmic; 974245
Cosmic; 1092599
Cosmic; 1305352
Cosmic; 1312337
Cosmic; 1436017
Cosmic; 1479602
Cosmic; 1676741
Cosmic; 1803942
Cosmic; 1998441
Cosmic; 2301977
Cosmic; 2811049
IARC_TP53; 18070
IARC_TP53; 21115
Progenetix; CVCL_1266
Proteomic databases PRIDE; PXD005235
PRIDE; PXD005942
PRIDE; PXD005946
PRIDE; PXD030304
Sequence databases EGA; EGAS00001000978
Entry history
Entry creation04-Apr-2012
Last entry update02-May-2024
Version number43